Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa.
BACKGROUND
The World Health Organization (WHO) recommends cough as the trigger for tuberculosis screening in human immunodeficiency virus (HIV)-infected patients, with acid-fast bacillus (AFB) smear as the initial diagnostic test. Our objective was to assess the yield and cost of a more intensive tuberculosis screening in HIV-infected patients starting antiretroviral therapy (ART) in Durban, South Africa.


METHODS
We prospectively enrolled adults, regardless of tuberculosis signs/symptoms, who were undergoing ART training from May 2007 to May 2008. After the symptom screen, patients expectorated sputum for AFB smear, tuberculosis polymerase chain reaction (PCR), and mycobacterial culture. Sensitivity and specificity of different symptoms and tests, alone and in combination, were compared with the reference standard of 6-week tuberculosis culture results. Program costs included personnel, materials, and cultures.


RESULTS
Of 1035 subjects, 487 (59%) were female; median CD4 cell count was 100 cells/microL. A total of 210 subjects (20%) were receiving tuberculosis treatment and were excluded. Of the remaining 825 subjects, 158 (19%) had positive sputum cultures, of whom 14 (9%) had a positive AFB smear and 82 (52%) reported cough. The combination of cough, other symptoms, AFB smear, and chest radiograph had 93% sensitivity (95% confidence interval, 88%-97%) and 15% specificity (95% confidence interval, 13%-18%). The incremental cost of intensive screening including culture was $360 per additional tuberculosis case identified.


CONCLUSIONS
Nearly 20% of patients starting ART in Durban, South Africa, had undiagnosed, culture-positive pulmonary tuberculosis. Despite WHO recommendations, neither cough nor AFB smear were adequately sensitive for screening. Tuberculosis sputum cultures should be performed before ART initiation, regardless of symptoms, in areas with a high prevalence of HIV and tuberculosis.
Bassett
Ingrid V
IV
Division of Infectious Disease, Massachusetts General Hospital, Boston, Massachusetts, USA. ibassett@partners.org
Wang
Bingxia
B
Chetty
Senica
S
Giddy
Janet
J
Losina
Elena
E
Mazibuko
Matilda
M
Bearnot
Benjamin
B
Allen
Jenny
J
Walensky
Rochelle P
RP
Freedberg
Kenneth A
KA
D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D001431:Bacteriological Techniques / Q000191:economics / Q000379:methods*; D004269:DNA, Bacterial / Q000235:genetics; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000191:economics / Q000379:methods*; D008853:Microscopy / Q000379:methods; D009169:Mycobacterium tuberculosis / Q000166:cytology / Q000235:genetics / Q000254:growth & development / Q000302:isolation & purification*; D016133:Polymerase Chain Reaction / Q000379:methods; D015995:Prevalence; D011446:Prospective Studies; D012680:Sensitivity and Specificity; D013019:South Africa; D013183:Sputum / Q000382:microbiology; D013194:Staining and Labeling / Q000379:methods; D014376:Tuberculosis / Q000175:diagnosis*
D019380:Anti-HIV Agents; D004269:DNA, Bacterial